Market Place
Sourcing Support
Anthos Therapeutics Shares New AZALEA-TIMI 71 Study Analysis
16 Nov 2024 //
GLOBENEWSWIRE
Anthos Therapeutics Appoints Will Kane as President & CFO Ramanan
31 Oct 2024 //
GLOBENEWSWIRE
Anthos Therapeutics Names New General Counsel And CHRO
10 Oct 2024 //
GLOBENEWSWIRE
Anthos Unveils AZALEA-TIMI 71 Study Analysis On Low Periprocedural Bleeding
02 Sep 2024 //
BUSINESSWIRE
Anthos: ~84% Eligible Patients Transitioned To Abelacimab In AZALEA Extension
06 Jun 2024 //
GLOBENEWSWIRE
Abelacimab`s cost-effectiveness analysis shows potential cost savings
06 May 2024 //
BUSINESSWIRE
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
22 Apr 2024 //
GLOBENEWSWIRE
Weeks after closing BMS deal, Karuna`s ex-CEO heads to Blackstone-backed Anthos
22 Apr 2024 //
ENDPTS
Anthos` Abelacimab, Demonstrated a 67% Reduction in Non-Major Bleeding
13 Nov 2023 //
BUSINESSWIRE
Study Confirming Reduction in Bleeding of Factor XI/XIa Inhibitor Abelacimab
26 Sep 2023 //
BUSINESSWIRE
Anthos Supported Global Survey of 3000+ Patients Prescribed Anticoagulants
26 Jun 2023 //
GLOBENEWSWIRE
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos
08 Jun 2023 //
GLOBENEWSWIRE
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact
09 May 2023 //
GLOBENEWSWIRE
New Assessment Scale to Capture Patient Relevant Bleeding to at ISPOR 2023
05 May 2023 //
GLOBENEWSWIRE
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab
03 Jan 2023 //
GLOBENEWSWIRE
US FDA grants Fast Track status for Anthos Therapeutics’ abelacimab
09 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Anthos Launches Second Phase 3 Clinical Trial of Abelacimab
25 Aug 2022 //
GLOBENEWSWIRE
Four New Sets of PC Data Further Expands the Evidence Supporting Abelacimab
13 Jul 2022 //
PRNEWSWIRE
Anthos Announces that Abelacimab has Received FDA FTD for Thrombosis
11 Jul 2022 //
BIOSPACE
Anthos Therapeutics to Host Discussion with Global Experts at 2022 BIO
13 Jun 2022 //
PRNEWSWIRE
Anthos Therapeutics Appoints Drew Young as CCO and Head of Patient Experience
26 May 2022 //
PRNEWSWIRE
Abelacimab: First Factor XI Inhibitor to Enroll Patients in PIII Trial
05 May 2022 //
PRNEWSWIRE
Anthos Therapeutics Partners with Lonza to Develop and MFG Abelacimab
11 Jun 2020 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.